Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697383 · ClinicalTrials.gov registry record · Phase 1
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02697383: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02697383 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697383, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Ixazomib (MLN9708)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-02 |
| Est. Completion | 2024-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697383
The ClinicalTrials.gov registry entry for NCT02697383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT02697383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697383 about?
NCT02697383 is a clinical study titled "Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study". The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
What is the current status of trial NCT02697383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-02. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT02697383?
The interventions under investigation include: Dexamethasone (DRUG), Ixazomib (MLN9708) (DRUG).
Who is sponsoring clinical trial NCT02697383?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.